DTIL
Precision Biosciences Inc (DTIL)
Healthcare • NASDAQ • $6.74-3.02%
- Symbol
- DTIL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.74
- Daily Change
- -3.02%
- Market Cap
- $175.71M
- Trailing P/E
- N/A
- Forward P/E
- -3.60
- 52W High
- $8.82
- 52W Low
- $3.53
- Analyst Target
- $29.60
- Dividend Yield
- N/A
- Beta
- 1.28
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transca…
Company websiteResearch DTIL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.